Raising Testosterone: Restore, Stimulate, or Replace?

Start with fertility and the axis

Exogenous testosterone raises the serum value by supplying hormone from outside the body. The hypothalamus and pituitary read that exposure as a reason to reduce LH and FSH. Intratesticular testosterone and sperm production can then fall even while the blood testosterone looks “better.”

Mechanism map

One signal loop controls two outcomes.

Blood testosterone and sperm production share an axis, but they are not the same measurement.

HypothalamusGnRH pulse
PituitaryLH + FSH
TestesIntratesticular response
circulating testosteroneBlood
sperm productionFertility

Circulating testosterone feeds back upstream

Restore: remove an upstream brake
Stimulate: increase the endogenous signal
Replace: add hormone downstream

A better serum number can coexist with a quieter endogenous axis.

That makes current or future fertility a pre-treatment question, not an adverse-effect footnote. The AUA/ASRM male-infertility guideline says exogenous testosterone should not be prescribed to men interested in current or future fertility. A semen analysis measures a different outcome from a testosterone panel; one cannot stand in for the other.

Suppression is often reversible, but “reversible” does not mean immediate or guaranteed. In controlled male-contraception studies, recovery usually took months and varied by baseline sperm count, exposure duration, and formulation. Those data came from selected healthy men. They do not promise the same recovery after prolonged replacement, mixed anabolic-androgenic steroid exposure, or pre-existing infertility.

Clinical decision fork

Put fertility before the medication list.

“Raise testosterone” hides three different jobs. The right branch begins with the state you are trying to change.

Is the low state real and reproducible?

Symptoms or signs · repeat morning testing · cause

Must fertility or endogenous production be preserved?

Current or future goals · testicular function · timeline

Then choose the job

Restore

Remove the brake

A reversible driver is present or still being tested.

Axis: Own signal stays online
Fertility: Usually least disruptive

Stimulate

Increase LH / FSH drive

A selected secondary state can still respond.

Axis: Signal is supplied or amplified
Fertility: May preserve or induce sperm

Replace

Add testosterone downstream

Deficiency is confirmed after cause evaluation.

Axis: LH / FSH turn down
Fertility: Sperm often falls

Separate questionBeyond physiologic replacement is enhancement—not a fourth path.

Start with replacement vs enhancement

Restore what is suppressing the signal

Restoration begins by proving that the low state persists under interpretable conditions. Current endocrine guidance still starts with symptoms or signs, accurate testing, and a repeat morning measurement, then uses LH and FSH to separate primary testicular failure from secondary hypothalamic or pituitary suppression. A low value during acute illness, severe energy deficit, medication exposure, or early recovery from anabolic drugs may be real without yet proving a permanent replacement indication.

Cause mapFind where the signal is being interrupted.

Functional load
Energy · metabolic health · illness · sleep
Medication or exposure
Opioids · glucocorticoids · alcohol · AAS / SARMs
Organic disease
Pituitary · prolactin · iron · testicular injury

CheckpointRepeat + classify

Symptoms or signs · morning testosterone · LH + FSH

Driver improvesRestore, then remeasure the outcome
Persistent or organic cluesChange the work-up or clinical owner

Three restoration boundaries

SleepTreat OSA for health; CPAP does not reliably raise testosterone. Untreated severe OSA changes the replacement plan.
MedicationReview with the prescriber; never stop an essential drug abruptly.
RecoveryHormone, symptom, and sperm timelines can diverge after AAS exposure.

Weight loss is associated with higher total and free testosterone in men with obesity, but the size of the rise varies and a laboratory improvement is not a guaranteed symptom response. Prior AAS or SARM exposure needs a disclosed product, timeline, and fertility goal; SARMs are not FDA-approved, FDA has not reviewed marketed products for safety or efficacy, they can cause serious harm, and no self-directed post-cycle recipe makes recovery certain.

Restoration is successful when the underlying condition improves and the named clinical outcome is reassessed—not merely when testosterone rises. Persistent, unequivocal deficiency after a reversible driver improves should reopen the diagnosis rather than trigger increasingly elaborate “optimization.”

Stimulate only when the axis can respond

Stimulation asks functioning testicular tissue to produce testosterone and, when fertility is the goal, sperm. It is therefore most coherent in selected secondary or hypogonadotropic states and less coherent when primary testicular failure is the bottleneck.

Signal leversThree strategies, one prerequisite: the axis must be able to respond.

First askCan the axis still answer a signal?

Selected secondary or hypogonadotropic state · functioning testicular tissue downstream

hCG ± FSH activity

Supply pituitary-like signalNarrow FDA-labeled use

Clomiphene / enclomiphene

Alter estrogen feedbackOff-label / not approved

Aromatase inhibitors

Reduce aromatizationConditional guideline option

Biochemical responseSymptom responseFertility or live birth

What the evidence labels mean

hCG ± FSH activityFDA labeling is limited to selected male hypogonadotropic states secondary to pituitary deficiency; FSH activity may also be needed for spermatogenesis.
Clomiphene / enclomipheneClomiphene use in men is off-label. Enclomiphene is not FDA approved and did not establish clinical benefit in its submitted program.
Aromatase inhibitorsSelected infertility use is conditional. Lower estradiol is not inherently better for bone, sexual, or metabolic physiology.

Short clomiphene, enclomiphene, hCG, and comparison trials can show a biochemical response or sperm preservation. They do not establish equivalent symptom benefit, long-term safety, pregnancy, or live-birth outcomes across strategies.

A higher testosterone level proves that the biochemical mechanism moved. It does not prove that the original symptom was androgen-mediated, that fertility improved, or that an off-label strategy is equivalent to replacement. Define the outcome before treatment; use semen testing when sperm is the outcome; and keep reproductive endocrinology or reproductive urology involved when pregnancy is time-sensitive.

Replace a confirmed deficiency—not a marketing target

Physiologic replacement is evidence-backed for men with compatible symptoms or signs and repeatedly low testosterone after appropriate evaluation. The goal is to restore physiologic exposure and a named clinical outcome—not to maximize a lab, recreate supraphysiologic trial results, or treat glycemia, body weight, or aging by proxy.

Topical, injected, oral, buccal, implantable, and other formulations can differ in peaks and troughs, transfer risk, blood-pressure effect, administration burden, and how a level must be timed. Those properties guide a clinician’s choice; they do not justify a consumer dosing table.

Monitoring has to match both the formulation and the person.

Reassessment loopDecide before treatment how it earns continuation.

Continuation testIs the intended outcome worth the tradeoff?

Name the outcomeFunction · timing · fertility goal
Measure in contextCorrect timing · semen when relevant
Watch safety boundariesHematocrit · pressure · adverse effects
Reassess the bargainBenefit · burden · changed priorities

Benefit is meaningful · boundaries are safeContinue and recheck

No benefit · new fertility goal · safety line crossedPause, change path, or change owner

The cardiovascular story requires current dates. In TRAVERSE, transdermal testosterone was noninferior to placebo for major adverse cardiovascular events in men aged 45–80 with symptoms, two low fasting tests, and cardiovascular disease or risk. That result does not apply to every formulation, population, or supraphysiologic exposure; atrial fibrillation, acute kidney injury, and pulmonary embolism were more frequent signals.

FDA removed the prior boxed-warning language about major cardiovascular events in 2025 and added class-wide blood-pressure warnings. In June 2026, FDA requested removal of the former age-related limitation after re-reviewing TRAVERSE, while its current information page still describes approved testosterone products as treatment for low testosterone with an associated medical condition. A proposed idiopathic-low-libido indication still requires supplemental approval. Regulatory movement does not replace diagnosis, fertility counseling, or outcome-based monitoring.

Compare the gain, give-up, and stop rule

Every path needs a predeclared benefit, burden, and exit. Open each row to compare the appropriate starting state, axis and fertility effect, reversibility, evidence confidence, monitoring burden, and the reason to stop or change owners.

Tradeoff explorer

Compare the path, not just the lab rise.

01RestoreGuideline-firstCause + repeat labs

Evidence position: Guideline-first for functional causes; the size and timing of a testosterone rise vary by cause.
Monitoring burden: The underlying condition, symptoms, standardized repeat hormone testing, and fertility testing when relevant.
Appropriate starting state: A low result may be functional or transient, and a reversible suppressor is present or still being evaluated.
Axis effect: No replacement signal is added. The aim is to remove the load suppressing hypothalamic, pituitary, or testicular function.
Fertility effect: Usually the least disruptive path, but correcting a driver does not guarantee normal sperm production.
Reversibility: The intervention targets the cause; recovery depends on whether the suppression was truly reversible.

May gain
Treat the condition that matters even if the testosterone change is small, while preserving the endogenous axis when possible.
Give up
It can be slower than starting a hormone, and the number may remain low when the cause is organic or mixed.
Stop or reassess
Escalate the diagnostic work-up when levels stay unequivocally low, symptoms progress, or pituitary or testicular signs appear.

02StimulateSelected / specialtyHormones + semen

Evidence position: Guideline-backed in specific infertility or hypogonadotropic states; otherwise specialty or off-label practice with narrower evidence.
Monitoring burden: Hormones, adverse effects, and semen analysis when pregnancy or preservation is an actual goal.
Appropriate starting state: Selected secondary hypogonadism or infertility with enough pituitary–testicular capacity to respond.
Axis effect: Gonadotropin signaling is supplied or increased rather than replaced by exogenous testosterone.
Fertility effect: Can preserve or induce sperm production in selected men; a serum rise alone does not prove fertility.
Reversibility: The drug effect ends after withdrawal, but the original cause and fertility timeline remain.

May gain
Raise endogenous testosterone while keeping gonadotropin or intratesticular signaling active in an appropriate responder.
Give up
More diagnostic precision, specialty ownership, monitoring, time, and uncertainty about symptom or live-birth benefit.
Stop or reassess
Reassess for primary testicular failure, pituitary disease, adverse effects, or a biochemical response without the intended outcome.

03ReplaceGuideline-backedOngoing safety

Evidence position: Guideline-backed for confirmed hypogonadism, with benefit and risk calibrated to population, outcome, formulation, and duration.
Monitoring burden: Clinical response, correctly timed testosterone, hematocrit, blood pressure, adverse effects, and risk-appropriate prostate follow-up.
Appropriate starting state: Symptoms or signs plus repeatedly low testosterone after the cause and major contraindications have been evaluated.
Axis effect: Exogenous testosterone supplies the circulating signal while suppressing LH, FSH, and endogenous production.
Fertility effect: Sperm production commonly falls. Recovery after stopping is variable and should not be promised on a calendar.
Reversibility: The medication can be stopped; recovery of the endogenous axis and spermatogenesis is a separate biological process.

May gain
Correct a confirmed deficiency with a formulation chosen around physiology, safety, burden, and patient priorities.
Give up
Endogenous-axis and fertility suppression, ongoing monitoring, formulation-specific burdens, and possible adverse effects.
Stop or reassess
Pause or reassess for a crossed safety boundary, a changed fertility goal, or no meaningful improvement in the outcome that justified treatment.

The comparison is intentionally at the path level. It does not choose a drug, formulation, dose, target, or monitoring interval for an individual.

Know when ownership must change

Some findings turn a general testosterone discussion into specialist work:

Handoff mapRoute the finding before escalating exposure.

Fertility
Time-sensitive goal or abnormal semen testing
Reproductive urology or endocrinology
Central axis
Low or inappropriately normal LH/FSH · pituitary clues
Endocrinology
Testicular
High LH/FSH · atrophy · mass · asymmetry
Primary testicular evaluation
Safety
Hematocrit · pressure · thromboembolism · prostate concern
Prompt treatment reassessment
Outcome
No meaningful improvement in the named goal
Reconsider the diagnosis

More exposure is not the automatic next step.

Why these handoffs matter

FertilityMatch sperm testing and treatment to the actual timeline, including before gonadotoxic treatment.
Central axisVery low testosterone, prolactin abnormalities, headache, or visual symptoms change the work-up and its urgency.
TesticularDo not reflexively stimulate when the tissue is the bottleneck.
SafetyEdema, new severe urinary symptoms, thromboembolism, hematocrit, or pressure concerns require reassessment with urgency matched to the finding.

Seeking muscle, strength, or body-composition effects beyond physiologic replacement is a different decision with a different risk frame. It is not a fourth treatment path hidden behind the word “optimize.” Start with why replacement and anabolic exposure cannot share one benefit estimate. The dedicated supraphysiologic guide in this series will own that question without providing cycles, stacks, or post-cycle recipes.

What this evidence cannot decide

Guidelines can define a diagnostic sequence and treatment boundaries. Trials can show that one strategy raises testosterone, preserves sperm concentration over a short interval, or changes a safety endpoint in a defined population. They cannot decide which symptom belongs to testosterone in one person, guarantee a pregnancy, predict recovery after prolonged suppression, or make a biochemical response clinically worthwhile.

The most important uncertainty is often upstream: whether the low state is functional, organic, transient, or mixed. The most important outcome is often not testosterone at all—it may be fertility, sexual function, anemia, bone health, recovery from energy deficiency, sleep, or control of a pituitary or testicular disorder.

Sources

Each source is paired with the claim it supports. Guideline, regulatory, trial, and review evidence are kept distinct so a short-term laboratory response is not presented as long-term clinical equivalence.

19 guideline, regulatory, trial, and review sources Claim-linked and decision-specific

Open bibliography

Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline
Bhasin S, Brito JP, Cunningham GR, et al.
J Clin Endocrinol Metab. 2018;103(5):1715–44
SupportsDiagnosis only when symptoms or signs coexist with consistently low testosterone; repeat morning testing; primary-versus-secondary classification; fertility, hematocrit, sleep-apnea, cardiovascular, prostate, response, and adverse-effect boundaries.
PMID 29562364
European Academy of Andrology guidelines on investigation, treatment and monitoring of functional hypogonadism in males
Corona G, Goulis DG, Huhtaniemi I, et al.
Andrology. 2020;8(5):970–87
SupportsFunctional hypogonadism requires symptoms plus repeated low morning testing after excluding organic disease; lifestyle, weight, and medication drivers should be addressed before or alongside hormone treatment.
PMID 32026626
2023 International Olympic Committee consensus statement on Relative Energy Deficiency in Sport
Mountjoy M, Ackerman KE, Bailey DM, et al.
Br J Sports Med. 2023;57(17):1073–97
SupportsLow energy availability can impair male reproductive function as part of a wider health and performance syndrome; restoration is nutritional and training care, not a rationale for anabolic exposure.
PMID 37752011
Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis
Corona G, Rastrelli G, Monami M, et al.
Eur J Endocrinol. 2013;168(6):829–43
SupportsDietary and surgical weight loss were associated with higher total and unbound testosterone, with larger rises after greater weight loss; observational and heterogeneous inputs limit individual prediction.
PMID 23482592
Effects of CPAP on testosterone levels in patients with obstructive sleep apnea: a meta-analysis study
Cignarelli A, Castellana M, Castellana G, et al.
Front Endocrinol. 2019;10:551
SupportsAcross prospective cohorts and two randomized studies, CPAP did not reliably raise testosterone; sleep-apnea treatment remains important for its own clinical outcomes rather than as a guaranteed hormone intervention.
PMID 31496991
Opioids and their endocrine effects: a systematic review and meta-analysis
de Vries F, Bruin M, Lobatto DJ, et al.
J Clin Endocrinol Metab. 2020;105(3):1020–29
SupportsChronic opioid exposure is associated with hypothalamic–pituitary–gonadal suppression; medication review must be coordinated with the treating prescriber rather than handled as abrupt self-discontinuation.
PMID 31511863
Physical, psychological and biochemical recovery from anabolic steroid-induced hypogonadism: a scoping review
Solanki P, Eu B, Smith J, Allan C, Lee K
Endocr Connect. 2023;12(12):e230358
SupportsRecovery after anabolic-androgenic steroid exposure varies across hormones, symptoms, testicular changes, and spermatogenesis, with sparse controlled evidence and timelines that can extend from months to years.
PMID 37855241
FDA warns of selective androgen receptor modulator use among teens and young adults
U.S. Food and Drug Administration
FDA consumer update
SupportsProducts marketed as SARMs are unapproved drugs that FDA has not reviewed for safety or efficacy; reported and potential harms include liver injury and cardiovascular, fertility, and sexual-function risks.
FDA consumer update
Diagnosis and treatment of infertility in men: AUA/ASRM guideline
American Urological Association and American Society for Reproductive Medicine
2020 guideline, amended 2024
SupportsDo not prescribe exogenous testosterone to men interested in current or future fertility; selected infertile men with low testosterone may receive an aromatase inhibitor, hCG, a SERM, or a combination, while evidence for adding such drugs to testosterone to preserve spermatogenesis is too limited to recommend.
AUA/ASRM guideline PDF
Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone
Kaminetsky J, Werner M, Fontenot G, Wiehle RD
BJU Int. 2016;117(4):677–85
SupportsIn two 16-week phase III trials in overweight men with secondary hypogonadism, enclomiphene increased testosterone, LH, and FSH and maintained sperm concentration while testosterone gel suppressed gonadotropins and sperm; clinical symptom and live-birth benefit were not established.
PMID 26496621
Clomiphene citrate and human chorionic gonadotropin are both effective in restoring testosterone in hypogonadism: a short-course randomized study
Habous M, Giona S, Tealab A, et al.
BJU Int. 2018;122(5):889–97
SupportsClomiphene, hCG, and their combination raised testosterone over three months in men seeking fertility preservation; short follow-up and absence of pregnancy or long-term safety endpoints limit equivalence claims.
PMID 29772111
Pregnyl (chorionic gonadotropin) prescribing information
U.S. Food and Drug Administration
FDA label. Revised 2023
SupportshCG is labeled for selected cases of male hypogonadotropic hypogonadism secondary to pituitary deficiency; this narrow indication does not make hCG a general testosterone booster.
FDA prescribing information
Clomid (clomiphene citrate) prescribing information
U.S. Food and Drug Administration
FDA label. Revised 2017
SupportsThe approved clomiphene label is for ovulatory dysfunction in women; use to raise testosterone in men is off-label and requires a separate evidence and monitoring discussion.
FDA prescribing information
Enclomiphene citrate: Pharmacy Compounding Advisory Committee review
U.S. Food and Drug Administration
FDA evidence review. June 2022
SupportsEnclomiphene trials showed biochemical and sperm effects, but FDA reviewers found no demonstrated clinically meaningful improvement in hypogonadal symptoms or quality of life; the submitted application did not receive approval.
FDA evidence review
Cardiovascular safety of testosterone-replacement therapy
Lincoff AM, Bhasin S, Flevaris P, et al.
N Engl J Med. 2023;389(2):107–17
SupportsIn 5,246 men aged 45–80 with symptoms, two low fasting tests, and cardiovascular disease or risk, transdermal testosterone was noninferior to placebo for major adverse cardiovascular events; atrial fibrillation, acute kidney injury, and pulmonary embolism were more frequent signals.
PMID 37326322
FDA issues class-wide labeling changes for testosterone products
U.S. Food and Drug Administration
FDA drug safety communication. February 2025
SupportsAfter reviewing TRAVERSE and ambulatory blood-pressure studies, FDA removed boxed-warning language about increased major cardiovascular events and required product-specific or class-wide warnings about increased blood pressure.
FDA labeling update
Testosterone information
U.S. Food and Drug Administration
FDA postmarket information. Updated June 2026
SupportsFDA requested removal of the age-related limitation after TRAVERSE while continuing to describe approved products as treatment for low testosterone with an associated medical condition.
Current FDA information
FDA takes step forward on testosterone therapy for men
U.S. Food and Drug Administration
FDA news release. April 16, 2026
SupportsFDA invited sponsors to discuss supplemental applications for a possible low-libido indication in men with idiopathic hypogonadism; any approval would still require substantial evidence of effectiveness and a favorable benefit-risk assessment.
FDA low-libido notice
Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis
Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C
Lancet. 2006;367(9520):1412–20
SupportsControlled male-contraception studies show that sperm recovery after suppressive androgen regimens takes months and varies with treatment and baseline factors; these data do not guarantee recovery after prolonged therapy, AAS use, or pre-existing infertility.
PMID 16650651

Professional educational reference based on the guidelines, regulatory sources, and peer-reviewed research listed under Sources. It is not individualized medical advice, does not diagnose hypogonadism or infertility, does not create a clinician–patient relationship, and does not recommend a drug, dose, target, or post-cycle protocol. Diagnosis, fertility planning, treatment, and monitoring belong with qualified clinicians using current guidance, labeling, and the full clinical history.